Compare SHOO & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | IRON |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 1993 | N/A |
| Metric | SHOO | IRON |
|---|---|---|
| Price | $36.53 | $73.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $42.75 | ★ $110.08 |
| AVG Volume (30 Days) | ★ 1.6M | 526.7K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $2,362,727,000.00 | N/A |
| Revenue This Year | $13.06 | N/A |
| Revenue Next Year | $12.67 | N/A |
| P/E Ratio | $45.72 | ★ N/A |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $19.05 | $30.82 |
| 52 Week High | $46.88 | $99.50 |
| Indicator | SHOO | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 33.10 | 41.49 |
| Support Level | $33.89 | $76.00 |
| Resistance Level | $46.88 | $83.93 |
| Average True Range (ATR) | 2.13 | 4.20 |
| MACD | -1.16 | 0.20 |
| Stochastic Oscillator | 20.63 | 13.69 |
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.